Article Data

  • Views 428
  • Dowloads 115

Reviews

Open Access

Replicating viruses for gynecologic cancer therapy

  • J.W. Park1
  • M. Kim2,*,

1Department of Obstetrics & Gynecology, Dankook University College of Medicine, Cheonan, South Korea

2Department of Medical Science, Dankook University College of Medicine, Cheonan, South Korea

DOI: 10.12892/ejgo3080.2016 Vol.37,Issue 3,June 2016 pp.395-304

Published: 10 June 2016

*Corresponding Author(s): M. Kim E-mail: manbok66@dankook.ac.kr

Abstract

Despite advanced therapeutic treatments, gynecologic malignancies such as cervical and ovarian cancers are still the top ten leading cause of cancer death among women in South Korea. Thus a novel and innovative approach is urgently needed. Naturally occurring viruses are live, replication-proficient viruses that specifically infect human cancer cells while sparing normal cell counterparts. Since the serendipitous discovery of the naturally oncotropic virus targeting gynecologic cancer in 1920s, various replicating viruses have shown various degrees of safety and efficacy in preclinical or clinical applications for gynecologic cancer therapy. Cellular oncogenes and tumor suppressor genes, which are frequently dysregulated in gynecologic malignancies, play an important role in determining viral oncotropism. Published articles describing replicating, oncolytic viruses for gynecologic cancers are thoroughly reviewed. This review outlines the discovery of replication-proficient virus strains for targeting gynecologic malignancies, recent progresses elucidating molecular connections between oncogene/tumor suppressor gene abnormalities and viral oncotropism, and the associated preclinical/clinical implications. The authors would also like to propose future directions in the utility of the replicating viruses for gynecologic cancer therapy.

Keywords

Replicating virus; Oncolytic virus; Gynecologic cancer; Oncogenes; Tumor suppressor genes.

Cite and Share

J.W. Park,M. Kim. Replicating viruses for gynecologic cancer therapy. European Journal of Gynaecological Oncology. 2016. 37(3);395-304.

References

[1] Daejeon Statistics Korea: “Korean Statistical Information Service”, 2012. Available at: http://kosis.kr.

[2] Fuh K.C., Shin J.Y., Kapp D.S., Brooks R.A., Ueda S., Urban R.R., et al.: “Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States”. Gynecol. Oncol., 2014, 16, pii: S0090-8258(14)01369.

[3] Roberts M.S., Lorence R.M., Groene W.S., Bamat M.K.: “Naturally oncolytic viruses”. Curr. Opin. Mol. Ther., 2006, 8, 314.

[4] Wang G., Barrett J.W., Stanford M., Werden S.J., Johnston J.B., Gao X., et al.: “Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor”. Proc. Natl. Acad. Sci. U S A, 2006, 103, 4640.

[5] Strong J.E., Coffey M.C., Tang D., Sabinin P., Lee P.W.: “The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus”. EMBO J., 1998, 17, 3351.

[6] Kim M., Williamson C.T., Prudhomme J., Bebb D.G., Riabowol K., Lee P.W., et al.: “The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status”. Oncogene, 2010, 29, 3990.

[7] De Pace N.G.: “Sulla scomparsa di un enorme cancro vegetante del collo dell’utero senza cura chirurgica”. Ginecologia, 1912, 9, 82. [8] Bzhalava D., Guan P., Franceschi S., Dillner J., Clifford G.: “A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types”. Virology, 2013, 445, 224.

[9] Whang J.D., Lee J.H.: “Molecular genetics of gynecologic cancer”. J. Korean Med. Sci., 1997, 12, 383.

[10] Bourhis J., Le M.G., Barrois M., Gerbaulet A., Jeannel D., Duvillard P., et al.: “Prognostic value of c-myc proto-oncogene overexpression in early invasive carcinoma of the cervix”. J. Clin. Oncol., 1990, 8, 1789.

[11] Mammas I.N., Zafiropoulos A., Spandidos D.A.: “Involvement of the ras genes in female genital tract cancer”. Int. J. Oncol., 2005, 26, 1241.

[12] Egan C., Kim M., Johnston R.N.: “Increased expression of human c- Myc renders cells sensitive to reovirus oncolysis”. AACR Annual General Meeting, Washington, DC, July 2003.

[13] Shih Ie M., Kurman R.J.: “Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis”. Am. J. Pathol., 2004, 164, 1511.

[14] Bauerschlag D.O., Schem C., Weigel M.T., Von Kaisenberg C., Strauss A., Bauknecht T., et al.: “The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer”. J. Cancer Res. Clin. Oncol., 2009, 136, 79.

[15] Hauptmann S., Denkert C., Koch I., Petersen S., Schlüns K., Reles A., et al.: “Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization”. Hum. Pathol., 2002, 33, 632.

[16] Shih I.M., Kurman R.J.: “Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges”. Clin. Cancer Res., 2005, 11, 7273.

[17] Meinhold-Heerlein I., Hauptmann S.: “The heterogeneity of ovarian cancer”. Arch. Gynecol. Obstet., 2014, 289, 237.

[18] Coffey M.C., Strong J.E., Forsyth P.A., Lee P.W.: “Reovirus therapy of tumors with activated Ras pathway”. Science, 1998, 282, 1332.

[19] Kim M., Chung Y.H., Johnston R.N.: “Reovirus and tumor oncolysis”. J Microbiol. 2007, 45, 187.

[20] Kuttler F., Mai S.: “c-Myc, Genomic Instability and Disease”. Genome Dyn., 2006, 1, 171.

[21] Prochownik E.V., Li Y.: “The ever expanding role for c-Myc in promoting genomic instability”. Cell Cycle, 2007, 6, 1024.

[22] Prochownik E.V.: “c-Myc: linking transformation and genomic instability”. Curr. Mol. Med., 2008, 8, 446.

[23] Coschi C.H., Dick F.A.: “Chromosome instability and deregulated proliferation: an unavoidable duo”. Cell Mol. Life Sci., 2012, 69, 2009.

[24] Douglas S.L., Ivan V.K., Charles E.R.: “Rhabdoviridae.” . In: Knipe D.M., Howley P.M. (eds). Fields Virology, 6th ed. Philadelphia: Lippincott- Raven, 2013, 1298.

[25] Liu Y.P., Steele M.B., Suksanpaisan L., Federspiel M.J., Russell S.J., Peng K.W., et al.: “Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer”. Gynecol. Oncol., 2014, 132, 194.

[26] Robert A.L., Griffith D.P.: “Paramyxoviridae”. In: Knipe D.M., Howley P.M. (eds). Fields Virology, 6th ed. Philadelphia: Lippincott- Raven, 2013, 1407.

[27] Asada, T.: “Treatment of human cancer with mumps virus”. Cancer, 1974, 34, 1907.

[28] Enders J.F., Peebles T.C.: “Propagation in tissue cultures of cytopathogenic agents from patients with measles”. Proc. Soc. Exp. Biol. Med., 1954, 86, 277.

[29] Enders J.F.: “Measles virus. Historical review, isolation, and behavior in various systems”. Am. J. Dis. Child., 1962, 103, 282.

[30] Hornick R.B., Schluederberg A.E., Mccrumb F.R. Jr.: “Vaccination with live attenuated measles virus”. Am. J. Dis. Child., 1962, 103, 344.

[31] Galanis E., Atherton P.J., Maurer M.J., Knutson K.L., Dowdy S.C., Cliby W.A., et al.: “Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer”. Cancer Res., 2015, 75, 22.

[32] Jones M.S. 2nd, Harrach B., Ganac R.D., Gozum M.M., Dela Cruz W.P., Riedel B., et al.: “New adenovirus species found in a patient presenting with gastroenteritis”. J. Virol., 2007, 81, 5978.

[33] Robinson C.M., Singh G., Henquell C., Walsh M.P., Peigue-Lafeuille H., Seto D., et al.: “Computational analysis and identification of an emergent human adenovirus pathogen implicated in a respiratory fatality”. Virology, 2011, 409, 141.

[34] Rowe W.P., Huebner R.J., Gilmore L.K., Parrott R.H., Ward T.G.: “Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture”. Proc. Soc. Exp. Biol. Med., 1953, 84, 570.

[35] Hilleman M.R., Werner J.H.: “Recovery of new agent from patients with acute respiratory illness”. Proc. Soc. Exp. Biol. Med., 1954, 85, 183.

[36] Arnold J.B.: “Adenoviridae”. In: Knipe D.M., Howley P.M. (eds). Fields Virology, 6th ed. Philadelphia: Lippincott- Raven, 2013, 2613.

[37] Smith R.R., Huebner R.J., Rowe W.P., Schatten W.E., Thomas L.B.: “Studies on the use of viruses in the treatment of carcinoma of the cervix”. Cancer, 1956, 9, 1211.

[38] Vasey P.A., Shulman L.N., Campos S., Davis J., Gore M., Johnston S., et al.: “Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer”. J. Clin. Oncol., 2002, 20, 1562.

[39] Pol J., Bloy N., Obrist F., Eggermont A., Galon J., Cremer I., et al.: “Trial watch: oncolytic viruses for cancer therapy”. Oncoimmunology, 2014, 3, e28694.

[40] Sabin A.B.: “Reoviruses. A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described”. Science, 1959, 130, 1387.

[41] Stanley N.F., Dorman D.C., Ponsford J.: “Studies on the pathogenesis of a hitherto undescribed virus (hepato-encephalomyelitis) producing unusual symptoms in suckling mice”. Aust. J. Exp. Biol. Med. Sci., 1953, 31, 147.

[42] Ramos-Alvarez M., Sabin A.B.: “Characteristics of poliomyelitis and other enteric viruses recovered in tissue culture from healthy American children”. Proc. Soc. Exp. Biol. Med., 1954, 87, 655.

[43] Jackson G.G., Muldoon B.L., Cooper G.S.: “Reovirus type 1 as an etiologic agent of the common cold”. J. Clin. Invest., 1961, 40, 1051.

[44] Ramos-Alvarez M., Sabin A.B.: “Intestinal viral flora of healthy children demonstrable by monkey kidney tissue culture”. Am. J. Public Health Nations Health, 1956, 46, 295.

[45] Rosen L., Evans H.E., Spickard A.: “Reovirus infections in human volunteers”. Am. J. Hyg., 1963, 77, 29.

[47] Bennette J.G.: “Isolation of a Non-pathogenic Tumour-destroying Virus from Mouse Ascites”. Nature, 1960, 187, 72.

[48] Nelson J.B., Tarnowsk G.S.: “An oncolytic virus recovered from Swiss mice during passage of an ascites tumour”. Nature. 1960, 188, 866.

[49] Bennette J.G., Bush P.V., Steele R.D.: “Characteristics of a newborn runt disease induced by neonatal infection with an oncolytic strain of reovirus type 3 (REO3MH). I. Pathological investigations in rats and mice”. Br. J. Exp. Pathol., 1967, 48, 251.

[50] Hashiro G., Loh P.C., Yau J.T.: “The preferential cytotoxicity of reovirus for certain transformed cell lines”. Arch. Virol., 1977, 54, 307.

[51] Duncan M.R., Stanish S.M., Cox D.C.: “Differential sensitivity of normal and transformed human cells to reovirus infection”. J. Virol., 1978, 28, 444.

[52] Loken S.D., Norman K., Hirasawa K., Nodwell M., Lester W.M., Demetrick D.J.: “Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (dearing 3) as an anticancer biotherapeutics”. Cancer Biol. Ther., 2004, 3, 734.

[53] Kim M., Egan C., Alain T., Urbanski S.J., Lee P.W., Forsyth P.A., et al.: “Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells”. Oncogene, 2007, 26, 4124.

[54] Kim M., Garant K.A., zur Nieden N.I., Alain T., Loken S.D., Urbanski S.J., et al.: “Attenuated reovirus displays oncolysis with reduced host toxicity”. Br. J. Cancer, 2011, 104, 290.

[55] Hirasawa K., Nishikawa S.G., Norman K.L., Alain T., Kossakowska A., Lee P.W.: “Oncolytic reovirus against ovarian and colon cancer”. Cancer Res., 2002, 62, 1696.

[56] Moss B.: “Poxviridae”. In: Fields B.N., Knipe D.M., and Howley P.M. (eds). Fields Virology, 6th ed. Philadelphia: Lippincott-Raven, 3292.

[57] Ellner P.D.: “Smallpox: gone but not forgotten”. Infection, 1998, 26, 263.

[58] Baxby D.: “The origins of vaccinia virus”. J. Infect. Dis., 1997, 136, 453.

[59] Wilkinson L.: “Jenner's smallpox vaccine. The riddle of vaccinia virus and its origin”. Med. Hist., 1982, 26, 94.

[60] Rosenthal S.R., Merchlinsky M., Kleppinger C., Goldenthal K.L.: “Developing new smallpox vaccines”. Emerg. Infect. Dis., 2001, 7, 920.

[61] Timiryasova T.M., Li J., Chen B., Chong D., Langridge W.H., Gridley D.S., et al.: “Antitumor effect of vaccinia virus in glioma model”. Oncol. Res., 1999, 11, 133.

[62] Chen B., Timiryasova T.M., Haghighat P., Andres M.L., Kajioka E.H., Dutta-Roy R., et al.: “Low-dose vaccinia virus-mediated cytokine gene therapy of glioma”. J. Immunother., 2001, 24, 46.

[63] Hung C.F., Tsai Y.C., He L., Coukos G., Fodor I., Qin L., et al.: “Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice”. Gene Ther., 2007, 14, 20.

[64] Kilham L., Herman C.M., Fisher E.R.: “Naturally occurring fibromas of grey squirrels related to Shope's rabbit fibroma”. Proc. Soc. Exp. Biol. Med., 1953, 82, 298.

[65] Sainsbury A.W., Nettleton P., Gilray J., Gurnell J.: “Grey squirrels have high seroprevalence to a parapoxvirus associated with deaths in red squirrels”. Anim. Conserv., 2000, 3, 229.

[66] Tompkins D.M., Sainsbury A.W., Nettleton P., Buxton D., Gurnell J.: “Parapoxvirus causes a deleterious disease in red squirrels associated with UK population declines”. Proc. Biol. Sci., 2002, 269, 529.

[67] Duff J.P., Scott A., Keymer I.F.: “Parapox virus infection of the grey squirrel”. Vet. Rec., 1996, 138, 527.

[68] Carroll B., Russell P., Gurnell J., Nettleton P., Sainsbury A.W.: “Epidemics of squirrel pox virus disease in red squirrels (Sciurus vulgaris): temporal and serological findings”. Epidemiol. Infect., 2009, 137, 257.

[69] Gurnell J.: “The grey squirrel in Britain: problems for management and lessons for Europe”. In: Mathias M.L., Santos-Reis M., Amori G., Libois R., Mitchell-Jones A., et al. (eds). European Mammals: Proceedings of the European Congress of Mammalogy. Lisbon: Museu Bocage, 1996, 67.

[70] Collins L.M., Warnock N.D., Tosh D.G., McInnes C., Everest D., et al.: “Squirrelpox virus: assessing prevalence, transmission and environmental degradation”. PLoS One, 2014, 9, e89521.

[71] Kim M., Ahn J.S., Yun C.O., Kim B.Y.: “Squirrel poxvirus as a novel oncolytic agent”. The 40th annual meeting of Korean Cancer Association. Seoul Korea, June 20, 2014.

[72] Kim M., Ahn J.S., Yun C.O., Kim B.Y.: “Therapeutic or preventive pharmacological composition of squirrelpox virus for anticancer therapeutics” (Translated in Korean). Korean patent No.: 10- 1370620 Date of Patent grant: Feb 27, 2014.

[73] Roizman B., Knipe D.M., Whitley R.J.. “Herpes Simplex viruses”. In: Knipe D.M., Howley P.M. (eds), Fields Virology, 6th ed. Philadelphia: Lippincott- Raven, 2013, 2803.

[74] Unna P.G.: “On herpes progenitalis, especially in women”. J. Cutan. Vener. Dis., 1883, 1, 321.

[75] Gruter W.: “Das herpesvirus, seine atiologische und klinische bedeutung”. Munch. Med. Wschr., 1924, 71, 1058.

[76] Chou J., Kern E.R., Whitley R.J., Roizman B.: “Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture”. Science, 1990, 250, 1262.

[77] Bolovan C.A., Sawtell N.M., Thompson R.L.: “ICP34.5 mutants of herpes simplex virus type 1 strain 17syn1 are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures”. J. Virol., 1994, 68, 48.

[78] Coukos G., Makrigiannakis A., Kang E.H., Rubin S.C,. Albelda S.M., Molnar-Kimber K.L.: “Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer”. Clin. Cancer Res., 2000, 6, 3342.

[79] Farassati F., Yang A.D., Lee P.W.: “Oncogenes in Ras signallingpathway dictate host- cell permissiveness to herpes simplex virus 1”. Nat. Cell. Biol., 2001, 3, 745.

[80] Fu X., Tao L., Zhang X.: “An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer”. Cancer Gene Ther., 2007, 14, 480.

[81] Le Boeuf F., Diallo J.S., McCart J.A., Thorne S., Falls T., Stanford M., et al.: “Synergistic interaction between oncolytic viruses augments tumor killing”. Mol. Ther., 2010, 18, 888.

[82] Alkassar M., Gärtner B., Roemer K., Graesser F., Rommelaere J., Kaestner L., et al.: “The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo”. J. Neurooncol., 2011, 104, 715.

[83] Balachandran S., Barber G.N.: “Vesicular stomatitis virus (VSV) therapy of tumors”. IUBMB Life, 2000, 50, 135.

[84] Peng K.W., Facteau S., Wegman T., O'Kane D., Russell S.J.: “Noninvasive in vivo monitoring of trackable viruses expressing soluble marker peptides”. Nat. Med., 2002, 8, 527.

[85] Dingli D., Peng K.W., Harvey M.E., Greipp P.R., O'Connor M.K., Cattaneo R., et al.: “Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter”. Blood, 2004, 103, 1641.

[86] Mader E.K., Butler G., Dowdy S.C., Mariani A., Knutson K.L., Federspiel M.J., et al.: “Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer”. J. Transl. Med., 2013, 11, 20.

[87] Kuhn I., Harden P., Bauzon M., Chartier C., Nye J., Thorne S., et al.: “Directed evolution generates a novel oncolytic virus for the treatment of colon cancer”. PLoS One, 2008, 3, e2409.

[88] Zhang Q., Yu Y.A., Wang E., Chen N., Danner R.L., Munson P.J., et al.: “Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus”. Cancer Res., 2007, 67, 10038.

[89] Sivendran S., Pan M., Kaufman H.L., Saenger Y.: “Herpes simplex virus oncolytic vaccine therapy in melanoma”. Expert Opin. Biol. Ther., 2010, 10, 1145.

[90] Galanis E., Hartmann L.C., Cliby W.A., Long H.J., Peethambaram P.P., Barrette B.A., et al.: “Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer”. Cancer Res., 2010, 70, 875.

[91] Chen B., Timiryasova T.M., Haghighat P., Andres M.L., Kajioka E.H., Dutta-Roy R., et al.: “Low-dose vaccinia virus-mediated cytokine gene therapy of glioma”. J. Immunother. 2001, 24, 46.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top